imipramine has been researched along with Breast Cancer in 4 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we demonstrate that the anti-depressant imipramine blocks growth of triple-negative (TNBC) and estrogen receptor-positive (ER+) breast cancers by inducing cell cycle arrest and by blocking heightened homologous recombination (HR) and non-homologous end joining-mediated (NHEJ) DNA repair activities." | 8.12 | The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events. ( Abdelfattah, N; Brenner, A; Chen, Y; Jatoi, I; Kaklamani, V; Nirzhor, S; Rajamanickam, S; Rao, A; Rao, MK; Subbarayalu, P; Timilsina, S; Vadlamudi, R; Viswanadhapalli, S, 2022) |
| " Here, we assessed the potential of imipramine blue (IB), a novel analogue of antidepressant imipramine, to suppress breast cancer growth and metastasis by inhibiting the ability of breast cancer cells to repair DNA strand breaks by homologous recombination (HR)." | 7.83 | Inhibition of FoxM1-Mediated DNA Repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis. ( Arbiser, JL; Bishop, AJ; Chen, Y; Gorthi, A; Hanes, MA; Ivanov, D; Kovalskyy, D; Onyeagucha, B; Panneerdoss, S; Rajamanickam, S; Rao, MK; Timilsina, S; Vadlamudi, RK, 2016) |
| " Here, we demonstrate that the anti-depressant imipramine blocks growth of triple-negative (TNBC) and estrogen receptor-positive (ER+) breast cancers by inducing cell cycle arrest and by blocking heightened homologous recombination (HR) and non-homologous end joining-mediated (NHEJ) DNA repair activities." | 4.12 | The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events. ( Abdelfattah, N; Brenner, A; Chen, Y; Jatoi, I; Kaklamani, V; Nirzhor, S; Rajamanickam, S; Rao, A; Rao, MK; Subbarayalu, P; Timilsina, S; Vadlamudi, R; Viswanadhapalli, S, 2022) |
| " Here, we assessed the potential of imipramine blue (IB), a novel analogue of antidepressant imipramine, to suppress breast cancer growth and metastasis by inhibiting the ability of breast cancer cells to repair DNA strand breaks by homologous recombination (HR)." | 3.83 | Inhibition of FoxM1-Mediated DNA Repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis. ( Arbiser, JL; Bishop, AJ; Chen, Y; Gorthi, A; Hanes, MA; Ivanov, D; Kovalskyy, D; Onyeagucha, B; Panneerdoss, S; Rajamanickam, S; Rao, MK; Timilsina, S; Vadlamudi, RK, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Timilsina, S | 2 |
| Rajamanickam, S | 2 |
| Rao, A | 1 |
| Subbarayalu, P | 1 |
| Nirzhor, S | 1 |
| Abdelfattah, N | 1 |
| Viswanadhapalli, S | 1 |
| Chen, Y | 2 |
| Jatoi, I | 1 |
| Brenner, A | 1 |
| Rao, MK | 2 |
| Vadlamudi, R | 1 |
| Kaklamani, V | 1 |
| Panneerdoss, S | 1 |
| Gorthi, A | 1 |
| Onyeagucha, B | 1 |
| Kovalskyy, D | 1 |
| Ivanov, D | 1 |
| Hanes, MA | 1 |
| Vadlamudi, RK | 1 |
| Bishop, AJ | 1 |
| Arbiser, JL | 1 |
| Roy, J | 1 |
| Vantol, B | 1 |
| Cowley, EA | 1 |
| Blay, J | 1 |
| Linsdell, P | 1 |
| Maguire, P | 1 |
| Hopwood, P | 1 |
| Tarrier, N | 1 |
| Howell, T | 1 |
1 trial available for imipramine and Breast Cancer
| Article | Year |
|---|---|
Treatment of depression in cancer patients.
Topics: Amitriptyline; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Depression; Fe | 1985 |
3 other studies available for imipramine and Breast Cancer
| Article | Year |
|---|---|
The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events.
Topics: Animals; Antidepressive Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Repair; | 2022 |
Inhibition of FoxM1-Mediated DNA Repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis.
Topics: Animals; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Repair; | 2016 |
Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line MCF-7.
Topics: Adenocarcinoma; Anti-Allergic Agents; Anti-Arrhythmia Agents; Astemizole; Breast Neoplasms; Cell Pro | 2008 |